Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Офтальмология / Английские материалы / Modern Concepts in Angiogenesis_Simons, Rubanyi_2007.pdf
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
4.21 Mб
Скачать

300 B. Ramlawi et al.

cells.51 In addition, complement fragment C5a causes neutophil adherence in venules but not in arterioles, suggesting that different mechanisms mediate neutrophil-endothelial adherence in the two vessel types.52

4.Endothelial Factors in Vascular Growth and Response to Injury

It is important to identify the role of nitric oxide and nitric oxide-related factors in vascular physiology and pathology as summarized in Fig. 10. Nitric oxide inhibits vascular smooth muscle proliferation via apoptosis. Animal models have shown that treatment with L-nitroarginine methyl ester (L-NAME), and inhibitor of NO formation, markedly increases neointimal development following vascular injury.53 Also,

Fig. 10. Schematic representation of endothelium and vascular smooth muscle demonstrating the multifaceted roles of nitric oxide released from the endothelium in the modulation of vascular function, structure, and the response to injury. cGMP, cyclic guanidine monophosphate. (Adapted from Ref. 71.)

Regulation of Coronary Vascular Tone and Microvascular Physiology

301

local transfection with the eNOS cDNA reduces the intimal proliferation which follows balloon injury.54 The vascular response to injury is enhanced in mice deficient in eNOS.55,56 Thus, NOand cyclic GMP elevating agents inhibit the growth of fibroblasts and vascular smooth muscle. This effect of NO on vascular smooth muscle growth is mediated by cGMP and can be mimicked by atrial natriuretic factor.56,57

NO plays an important role in supporting the process of angiogenesis; since endothelial cells do not seem to be sensitive to the growth inhibitory effects of nitric oxide. In fact, vascular endothelial growth factor (VEGF) actions during angiogenesis are mediated by NO (see Chapter 14). Endothelial cells in the proliferative phase have a six-fold increase in eNOS expression compared to confluent ones and eNOS knockout mice have little VEGF activity.19 During the vascular injury response, this feed-forward condition promotes vascular growth — since while endothelial cells are proliferating to form new blood vessels, the high levels of NO promote tube formation. Similarly, in response to the denudation injury, proliferating endothelial cells increase NO production during the growth period to compensate for the lack of endothelial cells in the denuded area while also decreasing platelet adhesion and vascular smooth muscle proliferation in that same area. Moreover, endothelial progenitor cells (EPC) from the bone marrow play a role in repair of denuded vessels as well as angiogenesis. While not completely elucidated, circulating EPCs seem to vary in quantity from one patient to the next depending on the presence of common risk factors such as diabetes (decreased amount) or lipid-lowering drugs such as HMG-Co A reductase inhibitors (increased amount).

5. Impact of Disease States on Coronary Circulation

Coronary microvascular homeostasis may be adversely affected in disease states through variation in their diameter, quantity or responsiveness to humoral factors. Vasomotor tone reliant on endothelial function is particularly vulnerable to pathology such as atherosclerosis, hyperlipidemia, diabetes or the aging process. This mechanism is highlighted in Fig. 11. The mechanisms underlying these abnormal endothelium-dependent responses are likely multifactorial. Factors responsible include abnormalities of G-protein signaling, resulting

302 B. Ramlawi et al.

Fig. 11. Reduced production/bioreactivity of endothelium-derived NO in the setting of atherosclerosis, diabetes, and many other pathological conditions. ADMA, asymmetrical dimethylarginine, acts as an antagonist of L-arginine. Superoxide (O2) and other oxygen free radicals may interfere with NO availability in conditions of increased oxidant stress. OONO, peroxynitrite radical may inhibit tetrahydrobiopterin (BH4), a cofactor for nitric oxide synthase (NOS). (Adapted from Ref. 71.)

in reduced activation of eNOS in response to endothelial cell receptor activation, an alteration of levels of the critical co-factor for eNOS tetrahydrobiopterin (BH4), and an overproduction of the asymmetric dimethylarginine (ADMA) which acts as an antagonist for the eNOS substrate L-arginine. It has been shown that oxidative stress (via increased production of vascular superoxide — O2) is particularly increased in the presence of common coronary risk factors. Such an increase in oxidative stress will cause a reduction in endotheliumdependent vasodilatation.

It is currently well proven that diseases that affect endothelialdependent vascular dilation impact the coronary microcirculation in addition to the larger vessels. Previous experiments have demonstrated that in coronary microvessels from monkeys fed a high cholesterol diet for 18 months, relaxations to acetylcholine, bradykinin, and the calcium ionophore A23187, were dramatically impaired or even produced paradoxical constrictions.58 Similar findings have been made in other

Regulation of Coronary Vascular Tone and Microvascular Physiology

303

animal models of diet-induced atherosclerosis. Subsequent studies performed using in vivo techniques showed that vasoconstriction caused by serotonin and ergonovine (both known to be modulated by the endothelium) was markedly enhanced in the coronary microcirculation of hypercholesterolemic monkeys.59 These findings are impressive because the coronary microcirculation is spared from the development of overt atherosclerosis. Therefore, in the setting of a risk factor for atherosclerosis, “endothelial dysfunction” occurs leading to an abnormal vascular response. Subsequently, diminished flow responses to acetylcholine have been demonstrated in humans with hypercholesterolemia that were restored with reduction of cholesterol levels.60 Similar observations have been made in either humans or experimental models of hypertension,61 ischemia-reperfusion52,62 and diabetes.63 It has also been suggested that this endothelial dysfunction plays a role in the development of clinical symptoms despite normal coronary anatomy. Table 2 summarizes studies demonstrating the effects hypercholesterolemia on coronary arterial microvessels.

Impaired endothelial-dependent vasodilation also has been linked to increased cardiovascular events. The loss of NO in cardiovascular disease not only leads to a decrease in vasodilation, but also predisposes to atherosclerotic lesion formation and vascular smooth muscle proliferation. NO also has antioxidant properties and prevents adhesion molecule expression by endothelial cells. An example of relevance to the clinical setting is the endothelial changes in the coronary microcirculation following cardioplegic arrest and cardiopulmonary bypass during cardiac surgery.64 In this setting, endothelial dysfunction persists for some time after cardiopulmonary bypass, and normalizes thereafter. This has important clinical implications, since it is common for patients undergoing coronary artery bypass grafting, with seemingly complete coronary revascularization, to exhibit signs of myocardial ischemia during the hours following surgery — likely caused by endothelial dysfunction.

Collateral vessels within the coronary circulation are particularly important in coronary disease. These allow for normal resting perfusion to a region of the myocardium that is served by an occluded vessel, albeit at a lower perfusion pressure. However, the coronary arterioles

Table 2. Functional alteration of coronary arterial microvessels by hypercholesterolemia.

 

 

 

 

Microvascular functional

Ref. no.

Material

Cholesterol feeding

Experiments

Vessel size

alteration

 

 

 

 

 

 

Rabbit

0.5% or 2%

In vitro

290 µm in

Reduced dilation to ACh,

78

 

cholesterol,

 

mean value

ADP

 

 

10–12 weeks

 

 

 

 

Monkey

0.7% cholesterol,

In vitro

12–220 µm

Enhanced contraction to

58

 

18 months

 

 

ACh; reduced dilation to

 

 

 

 

 

BK, A23187

 

Monkey

0.8% cholesterol,

In vivo

< 190 –

Increase in microvascular

59

 

18 months

microvascular

350µm

resistance to 5-HT

 

 

 

pressure

 

 

 

Monkey

0.7% cholesterol,

In vitro

100–200 µm

Reduced dilation to ADP,

79

 

8–12 weeks or

 

 

5-HT; paradoxical

 

 

18–80 weeks

 

 

constriction to thrombin;

 

 

 

 

 

hyperconstriction to TXA,

 

 

 

 

 

analogue

 

Pig

3% cholesterol,

In vitro

30–70 µm

Reduced dilation to flow,

80

 

16–20 weeks

 

 

ADP,

 

 

 

 

300µm

5-HT histamine, BK

 

Monkey

0.7% cholesterol,

In vivo

Enhanced constriction to

81

 

25 months

 

 

5-HT in mean value

 

Pig

2% cholesterol,

In vitro

300–480 µm

Enhanced constriction to

82

 

10–13 weeks

 

 

HT-1, S6c in mean value

 

Human

CAD patients

In vitro

57–183 µm

Reduced dilation to HGF,

83

 

 

 

 

VEGF

 

CAD, Coronary arterial disease; S6c, semafotoxin, ETB receptor agonist.

Source: Adapted from Ref. 2.

.al et Ramlawi .B 304